{"pmid":32372784,"pmcid":"PMC7195307","title":"Puzzle over viral load.","text":["Puzzle over viral load.","We don't yet know if being exposed to more coronavirus particles leads to more severe covid-19 symptoms, reports Linda Geddes.","New Sci","Geddes, Linda","32372784"],"abstract":["We don't yet know if being exposed to more coronavirus particles leads to more severe covid-19 symptoms, reports Linda Geddes."],"journal":"New Sci","authors":["Geddes, Linda"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32372784","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/S0262-4079(20)30658-8","topics":["General Info"],"weight":1,"_version_":1666138496329318401,"score":9.490897,"similar":[{"pmid":32287798,"pmcid":"PMC7130662","title":"Will heat kill the coronavirus?","text":["Will heat kill the coronavirus?","We don't know if changing seasons will help stem the outbreak, says Michael Le Page.","New Sci","Le Page, Michael","32287798"],"abstract":["We don't know if changing seasons will help stem the outbreak, says Michael Le Page."],"journal":"New Sci","authors":["Le Page, Michael"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32287798","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/S0262-4079(20)30377-8","topics":["General Info"],"weight":1,"_version_":1666138491373748224,"score":96.067276},{"pmid":32348943,"pmcid":"PMC7194795","title":"Could India be the origin of next COVID-19 like epidemic?","text":["Could India be the origin of next COVID-19 like epidemic?","The COVID-19 global pandemic is not even over yet but it has already taught us a lot of lessons - the hard way. The vast majority of the global community has blamed the Chinese Illegal wildlife markets for the origin of this pandemic. Through careful scientific analysis, I have explained in this article that we don't need such wildlife markets for these kinds of outbreaks to occur in the future. I have also explained how India which is the second-most populous country in the world, could be the origin of the next outbreak, even though such wildlife markets are either very rare or do not exist at all in India.","Sci Total Environ","Minhas, Sachin","32348943"],"abstract":["The COVID-19 global pandemic is not even over yet but it has already taught us a lot of lessons - the hard way. The vast majority of the global community has blamed the Chinese Illegal wildlife markets for the origin of this pandemic. Through careful scientific analysis, I have explained in this article that we don't need such wildlife markets for these kinds of outbreaks to occur in the future. I have also explained how India which is the second-most populous country in the world, could be the origin of the next outbreak, even though such wildlife markets are either very rare or do not exist at all in India."],"journal":"Sci Total Environ","authors":["Minhas, Sachin"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32348943","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.scitotenv.2020.138918","keywords":["covid-19","coronavirus","outbreak","pandemic"],"locations":["Chinese","India","India","India"],"countries":["India","China"],"countries_codes":["IND|India","CHN|China"],"topics":["General Info"],"weight":1,"_version_":1666138495371968512,"score":63.559547},{"pmid":32333818,"title":"COVID-19: lambda interferon against viral load and hyperinflammation.","text":["COVID-19: lambda interferon against viral load and hyperinflammation.","Coronavirus Disease 2019 (COVID-19), triggered by the betacoronavirus SARS-CoV-2, has become one of the worst pandemics of our time that has already caused more than 183,470 deaths [JHU data-23/04/2020, https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9 ecf6]. Effective therapeutic approaches are urgently needed to reduce the spread of the virus and its death toll. Here, we assess the possibility of using interferon lambda (IFNlambda), a third type of interferon sharing low homology with type I IFNs and IL-10, for treating COVID-19 patients. We discuss the unique role of IFNlambda in fine-tuning antiviral immunity in the respiratory tract to achieve optimal protection and minimal host damage and review early evidence that SARS-CoV-2 may impair IFNlambda induction, leading to a delayed type I IFN-dominated response that triggers hyperinflammation and severe disease. We also consider the potential windows of opportunity for therapeutic intervention with IFNlambda and potential safety considerations. We conclude that IFNlambda constitutes a promising therapeutic agent for reducing viral presence and hyperinflammation in a single shot to prevent the devastating consequences of COVID-19 such as pneumonia and acute respiratory distress syndrome (ARDS).","EMBO Mol Med","Andreakos, Evangelos","Tsiodras, Sotirios","32333818"],"abstract":["Coronavirus Disease 2019 (COVID-19), triggered by the betacoronavirus SARS-CoV-2, has become one of the worst pandemics of our time that has already caused more than 183,470 deaths [JHU data-23/04/2020, https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9 ecf6]. Effective therapeutic approaches are urgently needed to reduce the spread of the virus and its death toll. Here, we assess the possibility of using interferon lambda (IFNlambda), a third type of interferon sharing low homology with type I IFNs and IL-10, for treating COVID-19 patients. We discuss the unique role of IFNlambda in fine-tuning antiviral immunity in the respiratory tract to achieve optimal protection and minimal host damage and review early evidence that SARS-CoV-2 may impair IFNlambda induction, leading to a delayed type I IFN-dominated response that triggers hyperinflammation and severe disease. We also consider the potential windows of opportunity for therapeutic intervention with IFNlambda and potential safety considerations. We conclude that IFNlambda constitutes a promising therapeutic agent for reducing viral presence and hyperinflammation in a single shot to prevent the devastating consequences of COVID-19 such as pneumonia and acute respiratory distress syndrome (ARDS)."],"journal":"EMBO Mol Med","authors":["Andreakos, Evangelos","Tsiodras, Sotirios"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333818","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.15252/emmm.202012465","keywords":["covid-19","cytokine storm","hyperinflammation","interferon","viral infection"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138493945905152,"score":53.36093},{"pmid":32287799,"pmcid":"PMC7131061","title":"Drug trials under way.","text":["Drug trials under way.","We'll soon know if covid-19 can be treated with drugs developed for HIV and Ebola, reports Alice Klein.","New Sci","Klein, Alice","32287799"],"abstract":["We'll soon know if covid-19 can be treated with drugs developed for HIV and Ebola, reports Alice Klein."],"journal":"New Sci","authors":["Klein, Alice"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32287799","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/S0262-4079(20)30376-6","topics":["General Info"],"weight":1,"_version_":1666138491370602497,"score":50.512424},{"pmid":32295895,"title":"Comparison of Copan Eswab and FLOQswab for COVID-19 PCR diagnosis: working around a supply shortage.","text":["Comparison of Copan Eswab and FLOQswab for COVID-19 PCR diagnosis: working around a supply shortage.","On March 16(th) 2020, WHO Director-General stated \"You cannot fight a fire blindfolded. And we cannot stop this [COVID-19] pandemic if we don't know who is infected. We have a simple message for all countries: test, test, test. Test every suspected case.\" (https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at -the-media-briefing-on-covid-19---16-march-2020) This strategy hinges on the availability of appropriate, validated collection and transport systems to ensure preservation of nucleic acids and compatibility with downstream molecular testing - an acute challenge in the current pandemic. We present direct comparison of COVID-19 specimens collected with FLOQswab Nasopharyngeal Swab preserved in universal transport medium (Copan UTM System, Copan, Italy, catalog No.305C), optimized for viral specimens, and flocked regular nylon tip swab preserved in liquid amies (Eswab Collection system, Copan, Italy, catalog No. 480C), optimized for bacterial specimens.","J Clin Microbiol","Vermeiren, Christie","Marchand-Senecal, Xavier","Sheldrake, Elena","Bulir, David","Smieja, Marek","Chong, Sylvia","Forbes, Jessica D","Katz, Kevin","32295895"],"abstract":["On March 16(th) 2020, WHO Director-General stated \"You cannot fight a fire blindfolded. And we cannot stop this [COVID-19] pandemic if we don't know who is infected. We have a simple message for all countries: test, test, test. Test every suspected case.\" (https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at -the-media-briefing-on-covid-19---16-march-2020) This strategy hinges on the availability of appropriate, validated collection and transport systems to ensure preservation of nucleic acids and compatibility with downstream molecular testing - an acute challenge in the current pandemic. We present direct comparison of COVID-19 specimens collected with FLOQswab Nasopharyngeal Swab preserved in universal transport medium (Copan UTM System, Copan, Italy, catalog No.305C), optimized for viral specimens, and flocked regular nylon tip swab preserved in liquid amies (Eswab Collection system, Copan, Italy, catalog No. 480C), optimized for bacterial specimens."],"journal":"J Clin Microbiol","authors":["Vermeiren, Christie","Marchand-Senecal, Xavier","Sheldrake, Elena","Bulir, David","Smieja, Marek","Chong, Sylvia","Forbes, Jessica D","Katz, Kevin"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32295895","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1128/JCM.00669-20","locations":["Copan","Italy","Copan","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"e_drugs":["Nylons"],"topics":["Diagnosis"],"weight":1,"_version_":1666138493293690880,"score":50.45992}]}